1.IntroductionIn hematogenous metastasis, circulating tumor cells (CTCs) shed from primary tumors, intravasate into blood vessels, travel through the circulatory system, and may form secondary tumors. Although CTCs are rare (on the order of 1 to 100 CTCs per mL of peripheral blood), their numbers have been shown to be associated with overall patient prognosis and response to treatment.1,2 Multi-cellular CTC clusters (CTCCs) are more rare than single CTCs but are purported to have 50 to 100 times higher metastatic potential.3–5 The primary method of counting and studying CTCs is liquid biopsy in which CTCs are isolated from blood samples.6 However, we and others have shown that CTC numbers in small blood samples are often not representative of the entire patient blood volume and may even fail to capture rare CTCs or CTCCs.7–11 Drawing blood samples also makes longitudinal small animal studies difficult, since non-terminal blood draws are typically limited to every two weeks without fluid replacement. Therefore, in vivo measurements of CTCs offer the ability to sample larger volumes of blood over short and long time periods to study CTC frequency and patterns. Several optical methods have been developed to detect circulating cells directly in the bloodstream in live animals or in humans, generally termed “in vivo flow cytometry” (IVFC).12 For example, photoacoustic IVFC relies on the photoacoustic effect for detection of pigmented cell types (such as melanoma)13,14 or cells labeled with absorbing exogenous contrast agents, such as carbon nanotubes.15 Other groups have developed and applied confocal fluorescence microscopy-based IVFC instruments for detection of CTCs labeled with organic fluorophores or modified to express fluorescent proteins (FPs).16–18 Our team developed “diffuse in vivo flow cytometry” (DiFC) to non-invasively detect and count rare, fluorescently labeled or FP expressing CTCs in small animals using diffuse light.12,19–22 In contrast to intravital microscopy-based methods, DiFC uses highly scattered light to probe large, relatively deep blood vessels in bulk tissue. Large vessels—for example in the tail or leg of a mouse—carry on the order of of blood per minute.20 In mice, suitable blood vessels are approximately 1 mm in depth, although we have showed that detection to 2 to 4 mm in tissue is feasible with suitable choice of wavelength and instrument geometry.23,24 Hence, DiFC allows for non-invasive sampling of large peripheral blood volumes and detection of rare cells to, for instance, show that CTC numbers generally increase over the course of disease development in mouse metastasis models, but that they can fluctuate significantly over 24-h periods.11,20,21 However, the DiFC systems we have developed thus far have been limited to detection of single fluorophores due to specially designed optical fiber bundles with integrated miniaturized filters and lenses that are not easily interchanged.20,21,25 Given this limitation, we are interested in exploring multiplexed experiments involving monitoring more than one population of cells concurrently with DiFC. This would permit study of CTC shedding in mice with tumors composed of cells of different phenotypes or two different tumors in the same animal. In this article, we report on the design of a two-color DiFC system designed to detect blue-green [green (FP); GFP] and orange (tdTomato) FPs simultaneously. We used the system to monitor CTC numbers in mice inoculated with both GFP and tdTomato expressing multiple myeloma (MM) cells. We demonstrated that the shedding rate of the two populations was uncorrelated. We also validated the ability of two-color DiFC to detect CTCCs containing the two fluorophores both in tissue-mimicking flow phantoms in vitro and in MM-bearing mice in vivo. 2.Materials and Methods2.1.Two-Color DiFC Instrument DiFCThe two-color DiFC system uses a similar design to our previously reported GFP-compatible b-DiFC system.11,21,25 The system uses a 488 nm laser coupled into two specially designed optical fiber probes. Each probe consists of a single source fiber surrounded by a ring of 8 detection fibers [Fig. 1(a)]. The probe tips have internal mounted filters to reduce fiber autofluorescence including a central 488 nm band-pass filter (BP-f) and a ring-shaped 503 nm long-pass filter (LP-f). The eight detection fibers are grouped into two bundles of four which each terminate on an output fiber coupler, emission band-pass filters, a second focusing lens, and photomultiplier tube (PMT). The two sets of detection fibers are interleaved in the probe tip as shown in Fig. 1(b). The tip can then be aligned on the skin surface above a major blood vessel, for instance the ventral tail artery of a mouse [Fig. 1(c)], to excite and detect FP-expressing circulating cells. GFP and tdTomato were chosen as target FPs. Both tdTomato and GFP can be excited by 488 nm light [tdTomato with lower efficiency than GFP, as shown in Fig. 1(d)], which simplified the instrument construction. To achieve this, one of the two fiber probe outputs is fitted with a 535/50 filter (ET535/50m; Chroma Technology Corporation, Bellows Falls, Vermont, United States) and 536/40 nm filter (FL-004682; IDEX Health and Science, LLC, Rochester, New York, United States) for GFP detection, and the other output with a 610/75 nm filter (ET610/75m; Chroma Technology Corporation) for tdTomato. As we show, the tdTomato and GFP emission spectra are sufficiently separated that the two emission filter sets allow detection of both FPs with minimal inter-channel “bleed” [Fig. 1(e)]. The brightness of tdTomato—up to 2 to 3 times brighter than GFP—allows for detectable emission despite the lower excitation efficiency with the 488 nm laser.26 The instrument uses two fiber probes that are placed on the skin surface, approximately above the blood vessel of interest [Fig. 1(c)]. The data from the four PMTs, resulting from the two fiber probes, can be visualized as four channels: probe 1 – green (P1-G), probe 1 – orange (P1-O), P2-G, and P2-O [Fig. 1(f)]. The use of two fiber probes allows us to determine the direction and speed of circulating GFP- and tdTomato-expressing cells. For example, a GFP+ cell moving in a blood vessel beneath probe 1 followed by probe 2 will be detected as peaks in light intensity on channels P1-G and P2-G with a time delay between peaks [Fig. 1(g)]. Similarly, tdTomato+ cells will be detected in channels P1-O and P2-O. This allows us to specifically identify cells moving in the blood vessel of interest as described further in the next section. 2.2.Signal Processing and CTC DetectionThe signal processing algorithm used for two-color DiFC follows the following steps, which is a modified version of our previously published algorithm:20,21,25
2.3.Cell Lines and CTC Clusters In Vitro2.3.1.Multiple myeloma cellsWe used MM.1S cells that had previously been modified to express GFP, firefly luciferase, and neomycin resistance genes (GFP-MM.1S). These cells were originally described by Dr. Rosen at Northwestern University and were previously authenticated by us with an external service (Bio-Synthesis Inc., Lewisville, Texas) to verify their MM.1S lineage.21 We also transduced unmodified MM.1S cells (CRL-2974; ATCC, Manassas, Virginia, United States) with a tdTomato and puromycin-resistance lentivirus, LV-EF1α-tdTOMATO-IRES-Puro (SL100323; SignaGen Laboratories, Frederick, Maryland). cells were placed in low protein binding microcentrifuge tubes (022431081; Eppendorf AG, Germany) with RPMI 1640 with no phenol red (11-835-030; Thermo Fisher Scientific Inc, Hampton, NH) containing 10% fetal bovine serum (FBS) and polybrene for 10 min at room temperature. Lentivirus was added to the incubating cells with a multiplicity of infection (MOI) of 15 for 2 h at 1200 g and 32°C. The cells were then resuspended in the lentiviral media and additional media and incubated for 24 h before the lentiviral media was removed. The cells were then treated with puromycin to select for the brightest cells. 2.3.2.Breast cancer cells4T1 cells (CRL-2539; ATCC) were transduced with the tdTomato lentivirus and a GFP lentivirus LV-EF1α-GFP-Puro (SL100269; SignaGen) to create two FP expressing cell lines. Cells were incubated in DMEM (11-995-065; Thermo Fisher Scientific) containing 10% FBS, polybrene, and lentivirus with MOI of 10 for 24 h. The lentiviral media was then removed, and the cells were treated with puromycin to select for bright cells. 2.3.3.BC-4T1 CTC clusters grown in vitroTo create multicellular clusters, 4T1 cells were incubated for 2 days on tissue culture treated six-well plates. The adherent cells were then washed with phosphate buffer solution (PBS) and suspended in fresh PBS by lifting them from the plates with a cell scraper (08-100-241; Thermo Fisher Scientific). 2FP clusters were formed by co-culturing GFP+ and tdTomato+ cells while 1FP clusters were made with GFP-only or tdTomato-only cultures. No additional drugs or reagents were used to encourage cluster formation. Figure 1(h) shows representative microscope images of in vitro single cells and in vitro-made clusters. 2.4.Optical Flow Phantom Experiments In VitroTo first validate the two-color DiFC system, we used a tissue-mimicking optical flow phantom as we have described previously.21 The phantom is a block of scattering plastic that approximately mimics the optical properties and autofluorescence of biological tissue in the visible range. We threaded strands of Tygon tubing (TGY-010-C; Small Parts, Inc., Seattle, Washington, United States) through a through-hole at 0.75 mm depth, mimicking the depth of a blood vessel in a mouse tail. A microsyringe pump is used to pass suspensions of GFP- and tdTomato-expressing cells at final suspension concentrations of approximately cells per mL for single cells and cells per mL for clusters (which corresponded to approximately CTCCs per mL) with a flow speed of per minute through the tubing. 2.5.Mouse Experiments In VivoAll mice were handled in accordance with Northeastern University’s Institutional Animal Care and Use Committee (IACUC) policies on animal care. Animal experiments were carried out under Northeastern University IACUC protocol #21-0412R. Mice were caged in groups of five or less, and all animals were fed a diet of low fluorescence animal chow (AIN 93M Mature Rodent Diet, Ziegler Feed, East Berlin, Pennsylvania, United States). We used an MM disseminated xenograft model (MM DXM) (which we have used previously21) with an equal mixture of GFP- and tdTomato-expressing MM.1S cells. 8-week-old male severe combined immunodeficient (SCID/Bg) mice (Strain code 250; Charles River Laboratories, Cambridge, Massachusetts, United States) were injected via tail vein with of PBS containing GFP-MM.1S cells and tdTomato-MM.1S cells (). DiFC scanning was performed on each mouse held under inhaled isoflurane when CTCs were expected to enter circulation days. Additionally, three NOD SCID Gamma (NSG) mice (Strain code 005557; The Jackson Laboratory, Bar Harbor, Maine, United States) were scanned with DiFC for control data. 2.6.Whole-Body Hyperspectral Fluorescence Cryo-imagingTo visualize the spatial distribution of GFP and tdTomato expressing cells in the MM DXM model, animals were euthanized and submerged in optimal cutting temperature compound in preparation for hyperspectral fluorescence cryo-imaging. This approach, as described elsewhere,25,27 produces high-resolution 3-D white light and fluorescence images of the entire animal by imaging the frozen specimen during automated serial sectioning. For this study, the specimen was imaged using a white light emitting diode (LED), a 530 nm LED (Mightex, Toronto, Ontario, Canada) with a 550 nm shortpass filter for tdTomato excitation, and a 470 nm LED (Mightex) with a 475 nm shortpass filter for GFP excitation. The resulting RGB and fluorescence image stacks were assembled and rendered using 3D slicer.28 In 3D slicer, the GFP and tdTomato tumors were first segmented from the fluorescence image stacks while removing regions of autofluorescence in the stomach and intestines. Next, the overlapping tumor regions expressing both GFP and tdTomato were created by determining the intersection between the GFP and tdTomato segmentations. Finally, the intersecting region was subtracted from both segmentations to generate distinct GFP, tdTomato, and overlapping regions. These segmentations were then rendered into 3-D models for visualization. 3.Results3.1.Two-Color DiFC Performance in PhantomWe first performed two-color DiFC in our flow phantom model in vitro [Fig. 2(a)] using suspensions of GFP+ and tdTomato+ MM or BC cells. The signals measured from cells expressing either of the FPs are readily distinguishable as they are primarily detected as peaks in either the green [GFP, Fig. 2(b)] or orange [tdTomato, Fig. 2(c)] channels. Our selected combination of FPs, filters, and phantom optical properties yielded very similar SNRs for both GFP+ and tdTomato+ cells [Figs. 2(d) and 2(e)]—MM cells of both fluorophores had a mean SNR of 28.3 dB while the BC GFP+ and tdTomato+ cells had mean SNRs of 34.1 and 34.0 dB, respectively. We also observed that some particularly bright individual cells and 1FP clusters result in peaks—one peak in the primary channel (green for GFP, orange for tdTomato) and one peak in the opposite channel due to fluorophore emission bleed [Fig. 2(f)]. However, we were able to distinguish these 1FP detections apart from detections of 2FP clusters as described in Sec. 2.2. To show this, we separately performed DiFC on suspensions of GFP+ and tdTomato+ MM cells (MM) and 1FP clusters (BC) in a phantom. We note that because MM cells are cultured in suspension they typically grow as individual cells and small clusters, whereas adherent 4T1 BC cells readily form large multicellular groupings in culture.29 For all detected peaks, the green and orange peak amplitudes are plotted in Fig. 3. The dashed curves show the maximum expected amplitude of fluorophore spectral bleed between green and orange detection channels [Eq. (1)]. As such, detections plotted between the dashed lines are determined by our algorithm to be 2FP (blue circles) multi-cellular clusters and all detections outside the lines are 1FP (small green or pink circles) from single cells or 1FP clusters. The TR value in Eq. (1) was estimated as 0.057 for GFP+ cells and 0.089 for tdTomato+ cells by calculating the highest TR values of the single-fluorophore phantom MM and BC data with Eq. (2) [Figs. 3(a) and 3(b)]. We note that we selected a ‘conservative’ threshold that accounted for the worst-case coincidence of signal noise and peak detection. As shown in Figs. 3(a) and 3(b), this resulted in no false positive identification of 2FP clusters when running 1FP suspensions of cells through the phantom. We also collected DiFC data of GFP+ clusters and tdTomato+ BC clusters through the phantom, either one FP at a time [Figs. 3(c) and 3(d)] or mixed in a combined suspension [Fig. 3(e)]. As shown, all detections were correctly identified as 1FP for the single FP cluster cases [Figs. 3(c) and 3(d)]. In the case of mixed 1FP cluster suspension [Fig. 3(e)], most detections were correctly identified as 1FP, although a small number were labeled as 2FP. This occurred for only a small proportion of detections (1.5%) during scans with high flow rates of 15.5 detections per minute. As such, we surmise that the errors were likely the result of coincident detections of both 1FP GFP+ and tdTomato+ clusters in the phantom (i.e., both passed through the diameter DiFC field of view at the same time), as opposed to incorrect classification of a single detection. Finally, we created 2FP clusters of BC CTCs by co-culturing GFP+ and tdTomato+ cells. Suspensions were passed through a phantom and scanned with two-color DiFC [Fig. 3(f)]. The resulting DiFC data showed both 1FP and 2FP detections, which were 53.9% and 46.1% of all peaks, respectively. There was a large variety of 2FP clusters, some with 50% GFP and 50% tdTomato and others with more GFP or tdTomato cells. 3.2.Two-Color DiFC in Multiple Myeloma Xenograft Model Mice In VivoWe next performed two-color DiFC on MM tumor bearing mice [Fig. 4]. Mice were injected with a suspension of GFP+ and tdTomato+ MM cells (1:1 ratio). MM cells are known to initially rapidly home to the bone marrow niche after injection, steadily proliferate and then circulate in the peripheral blood in increasing numbers over time.21 Since cells were otherwise identical (aside from FP expression), we expected this proliferation would occur at approximately the same rate for both GFP+ and tdTomato+ cells. Representative two-color DiFC data measured periodically during tumor growth are shown in Figs. 4(a)–4(d). Here, Figs. 4(a) and 4(b) are raster plots, where each vertical line represents a DiFC detection of a GFP+ and tdTomato+ MM cell, respectively. When plotted together [Figs. 4(c) and 4(d)] we found that the number of both CTC types were, as expected, observed at approximately the same frequency and rate of increase. 3.3.Correlation of GFP and tdTomato CTCsWe also visualized DiFC CTC detections as moving averages, where CTCs are counted in 2-min moving intervals through the scan. Figure 5 shows a representative DiFC scan with individual cell detections [Fig. 5(a)] and moving averages through the scan for GFP [Fig. 5(b)] and tdTomato [Fig. 5(c)] detections. These data are typical of DiFC measurements,11 with transient periods of higher and lower detection rates observed during the scan for both GFP+ and tdTomato+ cells. An open question was whether this variation in count rates is due to short-term variations in CTC shedding from tumor into circulation, or transient changes in cardiovascular output (and therefore DiFC blood volume sampling) while mice are under inhaled anesthesia. We investigated the correlation between the paired moving averages of GFP and tdTomato detections using the Pearson correlation coefficient (PCC) as shown in Fig. 5(d). For this scan, a PCC of 0.345 was obtained, suggesting only a weak correlation between the GFP and tdTomato detection rates (-value of 0.018). Likewise, we calculated the PCC for all DiFC scans in this study with overall detection rates of at least 0.5 CTCs detected per minute, as shown in Fig. 5(e). Overall, the PCC data showed weak positive correlation between the channels (median PCC of 0.186 and mean of 0.199). Since GFP and tdTomato detection rates are poorly correlated, this suggests that temporal fluctuations are due to transient changes in rates of CTC shedding into the bloodstream, as opposed to changes in vascular output. 3.4.CTC Clusters in Multiple Myeloma MiceA total of 260 peaks were detected in the MM mice over a total 18 h of DiFC data. These are plotted in Fig. 6(a). Our analysis determined that 13.5% were 2FP detections [representative example is shown in Fig. 6(b)] and 86.5% were 1FP detections [representative example is shown in Fig. 6(c)]. We further estimated the size of the CTC clusters based on the combined peak amplitudes as summarized in Figs. 6(d) and 6(e). CTCCs are defined as two or more cells traveling together in circulation, or three or more nuclei travelling together in circulation. The latter definition excludes the possibility of a single CTC undergoing mitosis being identified as a CTCC.5 Therefore, in our calculations, 1FP detections that had amplitudes consistent with three or more GFP+ or tdTomato+ nuclei were considered 1FP clusters (89.3% of 1FP detections). 2FP detections contained at least one GFP- and tdTomato-expressing CTC, so that all 2FP detections were considered 2FP CTCCs. In combination, CTC clusters of either type (1FP or 2FP) represented 14.6% of all CTC detections. This is similar to the rate that we previously reported in a GFP-only MM tumor model.21 Figure 6(d) shows a histogram of cluster sizes for measured 2FP clusters (mean size = 9.3 cells; median size = 3 cells), and Fig. 6(e) shows a histogram of clusters sizes for measured 1FP clusters (mean size = 23.4 cells; median size = 16). The difference in estimated mean sizes here is due to the two (disparate) definitions used. However, in general this distribution of sizes is also similar to our previous work.21 We further note that we manually curated our CTCC detections after automated raw data processing and removed suspected artifacts, e.g., 2FP detections that appeared to arise from a motion artifact, or high amplitude (greater than 1500 mV) detections that saturated one of the detector PMTs and gave inaccurate estimation of the relative peak intensities. 3.5.Whole-Body Hyperspectral Fluorescence Cryo-ImagingAfter completion of DiFC scanning we performed whole-body hyperspectral fluorescence cryo-imaging of tumor bearing mice. Compared to whole body planar fluorescence or bioluminescence imaging techniques,30 cryo-imaging provides significantly superior spatial resolution and quantification of fluorescence signals.27 Based on prior characterization of the MM DXM model, we expected tumor to proliferate in the skeleton of the mouse.31 Hyperspectral fluorescence cryo-imaging confirmed these expectations, with GFP+ and tdTomato+ tumor appearing along and inside the spine, and within the brain, skull, scapula, humerus, femur, ribs and muscles of the legs, and arms. As shown in the whole-body rendering of a representative mouse [Fig. 7(a)] nearly all bulk tumor appeared to be single-FP, as opposed to homogenously mixed 2FP tumors. These data are consistent with our observation that most detected CTCCs were 1FP with relatively few 2FP CTCCs. Upon close investigation of the spine in Fig. 7(b), two examples of mixed tumors can be seen in blue. One of the 2FP tumors is further visualized in sagittal and axial cross-sectional views along the spine in Figs. 7(c) and 7(d). Overall, though, mixed tumors represented only a small fraction of the total observed tumor volume. 4.Discussion and ConclusionsWe previously developed several single-color DiFC systems that can non-invasively enumerate single-FP expressing CTCs to allow monitoring of metastatic dissemination in mice.20–22 In this work, we developed and validated a two-color DiFC system that allows us to simultaneously detect populations of GFP and tdTomato expressing CTCs. While multi-wavelength (multiplexed) intravital microscopy based methods of monitoring cells in blood flow have been reported previously,32–34 we have combined two-color detection with the advantages of DiFC which uses diffuse light to scan much larger volumes of blood than microscopy-based methods. Photoacoustic IVFC multiplexing has also been developed, which uses the photoacoustic effect to detect pigmented cells (such as melanoma) or cells labeled with absorbing contrast agents, such as carbon nanotubes.15 Detection of two similar CTC populations within the same mice allowed us to confirm that fluctuations in DiFC detections were unlikely due to changes in blood flow in the DiFC field of view (e.g., due to cardiovascular effects of the isoflurane anesthesia). The weak or moderate correlation between GFP+ and tdTomato+ detections therefore supports the notion that observed fluctuations in CTC numbers were caused by rates of CTC shedding from tumors and rapid clearance from circulation.11,35 Additionally, two-color DiFC allowed for detection of CTC clusters in cases where CTCCs contain cells expressing both FPs. The mouse tumor model studied here had evidence of some 2FP clusters; however, most CTCC detections were either GFP+ or tdTomato+ only. Post-mortem whole-body hyperspectral fluorescence cryo-imaging showed that the vast majority of the MM tumor volume in and adjacent to the bone expressed a single FP. Small regions of overlap [e.g., Figs. 7(c) and 7(d)] were observed, although the apparent mixing may be at least partly due to the resolution limits of the cryomacrotome system. Since we injected a mixed suspension of GFP+ and tdTomato+ MM cells at the time of inoculation, these data suggest that initial tumors were formed by single MM cells that homed to bone marrow and proliferated into tumor masses, as opposed to groups of MM cells forming masses. Therefore, there were few tumor masses composed of a mixture of GFP and tdTomato expressing cancer cells. This is consistent with the prevalence of 1FP CTCCs in our DiFC measurements and rarity of 2FP CTCCs. This is also consistent with prior work in breast cancer bearing mice which showed that mice implanted with two, single-FP expressing tumors in bilateral breast pads formed metastases that also primarily expressed single FPs.3 We note that the data suggests that while initial tumors were formed by single MM tumor cells, it is possible (or likely) that subsequent proliferation through the bloodstream may have been facilitated by shedding of CTCCs, which are known to have higher metastatic potential.3–5 We also noted that false positive 2FP detections could occur due to rare motion artifacts or when two CTCs of different FPs flow past the DiFC probes at similar times. Here, these cases were identified by manual operator inspection. In the future, more rigorous signal processing and pattern recognition methods could be used to better discriminate 2FP CTC clusters. Improved processing will facilitate further experiments with solid tumor models with more abundant 2FP clusters. In summary, two-color DiFC facilitates a large range of experiments in which two populations of cells can be studied. For instance, anti-cluster therapies could be studied longitudinally.36 We could also observe the CTC shedding patterns of two subpopulations of cancer cells in the same tumor or in two tumors. This could allow study of a therapeutic’s effects on treatment-resistant and -responsive cancer cells within the same mouse, reducing inter-mouse variability when studying these tumors in separate mice.37 Additionally, two completely different cell types could be detected, such as CTCs and tumor-associated macrophages to observe how the latter influences the development of metastases.38 Although the focus of the present study was development and validation of a small animal pre-clinical research system, in our lab we are also studying potential clinical translation of DiFC through the use of molecularly-targeted contrast agents.22,39,40 DisclosuresThe authors have no relevant financial interests in this article and no potential conflicts of interest to disclose. Code and Data AvailabilityThe data presented in this article are publicly available in the Pennsieve repository at DOI: 10.26275/q2w0-keol. The archived version of the code described in this article can be freely accessed through the GitHub repository at https://github.com/mark-niedre/Two-ColorDiFC AcknowledgmentsThis work was funded by the National Institutes of Health (Grant No. NIH-NCI 1R01CA260202). ReferencesC. Alix-Panabieres, H. Schwarzenbach and K. Pantel,
“Circulating tumor cells and circulating tumor DNA,”
Annu. Rev. Med., 63 199
–215 https://doi.org/10.1146/annurev-med-062310-094219
(2012).
Google Scholar
D. Lin et al.,
“Circulating tumor cells: biology and clinical significance,”
Signal Transduct. Target Ther., 6
(1), 404 https://doi.org/10.1038/s41392-021-00817-8
(2021).
Google Scholar
N. Aceto et al.,
“Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis,”
Cell, 158
(5), 1110
–1122 https://doi.org/10.1016/j.cell.2014.07.013 CELLB5 0092-8674
(2014).
Google Scholar
K. J. Cheung et al.,
“Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters,”
Proc. Natl. Acad. Sci. U. S. A., 113
(7), E854
–E863 https://doi.org/10.1073/pnas.1508541113
(2016).
Google Scholar
A. Fabisiewicz and E. Grzybowska,
“CTC clusters in cancer progression and metastasis,”
Med. Oncol., 34
(1), 12 https://doi.org/10.1007/s12032-016-0875-0
(2017).
Google Scholar
C. Alix-Panabieres and K. Pantel,
“Circulating tumor cells: liquid biopsy of cancer,”
Clin. Chem., 59
(1), 110
–118 https://doi.org/10.1373/clinchem.2012.194258
(2013).
Google Scholar
A. G. Tibbe, M. C. Miller and L. W. Terstappen,
“Statistical considerations for enumeration of circulating tumor cells,”
Cytometry A, 71
(3), 154
–162 https://doi.org/10.1002/cyto.a.20369
(2007).
Google Scholar
A. L. Allan and M. Keeney,
“Circulating tumor cell analysis: technical and statistical considerations for application to the clinic,”
J. Oncol., 2010 426218 https://doi.org/10.1155/2010/426218
(2010).
Google Scholar
Z. S. Lalmahomed et al.,
“Circulating tumor cells and sample size: the more, the better,”
J. Clin. Oncol., 28
(17), e288
–e289 https://doi.org/10.1200/JCO.2010.28.2764 JCONDN 0732-183X
(2010).
Google Scholar
M. A. Juratli et al.,
“Dynamic fluctuation of circulating tumor cells during cancer progression,”
Cancers, 6
(1), 128
–142 https://doi.org/10.3390/cancers6010128
(2014).
Google Scholar
A. L. Williams et al.,
“Short-term circulating tumor cell dynamics in mouse xenograft models and implications for liquid biopsy,”
Front. Oncol., 10 601085 https://doi.org/10.3389/fonc.2020.601085 FRTOA7 0071-9676
(2020).
Google Scholar
C. Hartmann et al.,
“Fluorescence detection, enumeration and characterization of single circulating cells in vivo: technology, applications and future prospects,”
Phys. Med. Biol., 63
(1), 01TR01 https://doi.org/10.1088/1361-6560/aa98f9 PHMBA7 0031-9155
(2017).
Google Scholar
E. I. Galanzha et al.,
“In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma,”
Sci. Transl. Med., 11
(496), eaat5857 https://doi.org/10.1126/scitranslmed.aat5857 STMCBQ 1946-6234
(2019).
Google Scholar
P. Hai et al.,
“Label-free high-throughput photoacoustic tomography of suspected circulating melanoma tumor cells in patients in vivo,”
J. Biomed. Opt., 25
(3), 036002 https://doi.org/10.1117/1.JBO.25.3.036002 JBOPFO 1083-3668
(2020).
Google Scholar
E. I. Galanzha et al.,
“In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells,”
Nat. Nanotechnol., 4
(12), 855
–860 https://doi.org/10.1038/nnano.2009.333 NNAABX 1748-3387
(2009).
Google Scholar
I. Georgakoudi et al.,
“In vivo flow cytometry: a new method for enumerating circulating cancer cells,”
Cancer Res., 64
(15), 5044
–5047 https://doi.org/10.1158/0008-5472.CAN-04-1058 CNREA8 0008-5472
(2004).
Google Scholar
V. V. Tuchin, A. Tarnok and V. P. Zharov,
“In vivo flow cytometry: a horizon of opportunities,”
Cytometry A, 79
(10), 737
–745 https://doi.org/10.1002/cyto.a.21143
(2011).
Google Scholar
Y. Suo, Z. Gu and X. Wei,
“Advances of in vivo flow cytometry on cancer studies,”
Cytometry A, 97
(1), 15
–23 https://doi.org/10.1002/cyto.a.23851
(2020).
Google Scholar
V. Pera et al.,
“Diffuse fluorescence fiber probe for in vivo detection of circulating cells,”
J. Biomed. Opt., 22
(3), 037004 https://doi.org/10.1117/1.JBO.22.3.037004 JBOPFO 1083-3668
(2017).
Google Scholar
X. Tan et al.,
“In vivo flow cytometry of extremely rare circulating cells,”
Sci. Rep., 9
(1), 3366 https://doi.org/10.1038/s41598-019-40143-2 SRCEC3 2045-2322
(2019).
Google Scholar
R. Patil et al.,
“Fluorescence monitoring of rare circulating tumor cell and cluster dissemination in a multiple myeloma xenograft model in vivo,”
J. Biomed. Opt., 24
(8), 085004 https://doi.org/10.1117/1.JBO.24.8.085004 JBOPFO 1083-3668
(2019).
Google Scholar
J. Pace et al.,
“Near-infrared diffuse in vivo flow cytometry,”
J. Biomed. Opt., 27
(9), 097002 https://doi.org/10.1117/1.JBO.27.9.097002 JBOPFO 1083-3668
(2022).
Google Scholar
F. Ivich et al.,
“Signal and measurement considerations for human translation of diffuse in vivo flow cytometry,”
J. Biomed. Opt., 27
(6), 067001 https://doi.org/10.1117/1.JBO.27.6.067001 JBOPFO 1083-3668
(2022).
Google Scholar
G. Blaney et al.,
“Dual-ratio approach for detection of point fluorophores in biological tissue,”
J. Biomed. Opt., 28
(7), 077001 https://doi.org/10.1117/1.JBO.28.7.077001 JBOPFO 1083-3668
(2023).
Google Scholar
J. E. Fitzgerald et al.,
“Heterogeneity of circulating tumor cell dissemination and lung metastases in a subcutaneous Lewis lung carcinoma model,”
Biomed. Opt. Express, 11
(7), 3633
–3647 https://doi.org/10.1364/BOE.395289 BOEICL 2156-7085
(2020).
Google Scholar
N. C. Shaner et al.,
“Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein,”
Nat. Biotechnol., 22
(12), 1567
–1572 https://doi.org/10.1038/nbt1037 NABIF9 1087-0156
(2004).
Google Scholar
D. Wirth et al.,
“Hyperspectral imaging and spectral unmixing for improving whole-body fluorescence cryo-imaging,”
Biomed. Opt. Express, 12
(1), 395
–408 https://doi.org/10.1364/BOE.410810 BOEICL 2156-7085
(2021).
Google Scholar
A. Fedorov et al.,
“3D Slicer as an image computing platform for the Quantitative Imaging Network,”
Magn. Reson. Imaging, 30
(9), 1323
–1341 https://doi.org/10.1016/j.mri.2012.05.001 MRIMDQ 0730-725X
(2012).
Google Scholar
S. Greenstein et al.,
“Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells,”
Exp. Hematol., 31
(4), 271
–282 https://doi.org/10.1016/S0301-472X(03)00023-7 EXHMA6 0301-472X
(2003).
Google Scholar
S. K. Cool et al.,
“Comparison of in vivo optical systems for bioluminescence and fluorescence imaging,”
J. Fluoresc., 23
(5), 909
–920 https://doi.org/10.1007/s10895-013-1215-9 JOFLEN 1053-0509
(2013).
Google Scholar
J. M. Runnels et al.,
“Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy,”
J. Biomed. Opt., 16
(1), 011006 https://doi.org/10.1117/1.3520571 JBOPFO 1083-3668
(2011).
Google Scholar
S. Boutrus et al.,
“Portable two-color in vivo flow cytometer for real-time detection of fluorescently-labeled circulating cells,”
J. Biomed. Opt., 12
(2), 020507 https://doi.org/10.1117/1.2722733 JBOPFO 1083-3668
(2007).
Google Scholar
J. Novak and M. Puoris’haag,
“Two-color, double-slit in vivo flow cytometer,”
Opt. Lett., 32
(20), 2993
–2995 https://doi.org/10.1364/OL.32.002993 OPLEDP 0146-9592
(2007).
Google Scholar
L. Zhang et al.,
“An optical platform for cell tracking in adult zebrafish,”
Cytometry A, 81
(2), 176
–182 https://doi.org/10.1002/cyto.a.21167
(2012).
Google Scholar
Z. Diamantopoulou et al.,
“The metastatic spread of breast cancer accelerates during sleep,”
Nature, 607
(7917), 156
–162 https://doi.org/10.1038/s41586-022-04875-y
(2022).
Google Scholar
R. Taftaf et al.,
“ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer,”
Nat. Commun., 12
(1), 4867 https://doi.org/10.1038/s41467-021-25189-z NCAOBW 2041-1723
(2021).
Google Scholar
R. M. Zemek et al.,
“Bilateral murine tumor models for characterizing the response to immune checkpoint blockade,”
Nat. Protoc., 15
(5), 1628
–1648 https://doi.org/10.1038/s41596-020-0299-3 1754-2189
(2020).
Google Scholar
C. Wei et al.,
“Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis,”
Mol. Cancer, 18
(1), 64 https://doi.org/10.1186/s12943-019-0976-4
(2019).
Google Scholar
R. A. Patil et al.,
“Fluorescence labeling of circulating tumor cells with a folate receptor-targeted molecular probe for diffuse In vivo flow cytometry,”
Mol. Imaging Biol., 22
(5), 1280
–1289 https://doi.org/10.1007/s11307-020-01505-9
(2020).
Google Scholar
M. Niedre,
“Prospects for fluorescence molecular in vivo liquid biopsy of circulating tumor cells in humans,”
Front. Photonics, 3 910035 https://doi.org/10.3389/fphot.2022.910035
(2022).
Google Scholar
BiographyAmber L. Williams received her BS degree in engineering physics from Miami University in 2018 and her PhD in bioengineering from Northeastern University in 2024. |
Cancer detection
Tumors
Green fluorescent proteins
In vivo imaging
Fluorescence
Animals
Tunable filters